[MEP therapy of advanced lung cancer].
Fourty-four patients with advanced non-small cell cancer of the lung were treated with a combination chemotherapy of mitomycin C, endoxan, and cisplatin (MEP). The overall response rate was 20%, with 9 partial responses. The median duration of response was 7 months. The overall median survival was 10 months. No significant difference was noted in survival time between PR and NC. MEP therapy seems to provide a relatively easy therapeutic approach in the treatment of advanced lung cancer with no associated renal toxicity or loss of hair.